This menu provides the list of EV proteins identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Protein name UniProt accession Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization.
Proteomics. 2006 Jan;6(1):153-71.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles derived from human colorectal cancer cells.
J Proteome Res. 2007 Dec;6(12):4646-55. Epub 2007 Oct 24.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles.
Proteomics. 2008 Jun;8(12):2430-46. doi: 10.1002/pmic.200701029.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles.
Proteomics. 2008 Jun;8(12):2430-46. doi: 10.1002/pmic.200701029.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Characterization of PKD protein-positive exosome-like vesicles.
J Am Soc Nephrol. 2009 Feb;20(2):278-88. doi: 10.1681/ASN.2008060564. Epub 2009 Jan 21.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).
J Proteome Res. 2009 Mar;8(3):1304-14. doi: 10.1021/pr800658c.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes.
J Cell Physiol. 2009 Oct;221(1):221-31. doi: 10.1002/jcp.21847.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomics characterization of cell membrane blebs in human retinal pigment epithelium cells.
Mol Cell Proteomics. 2009 Oct;8(10):2201-11. doi: 10.1074/mcp.M900203-MCP200. Epub 2009 Jun 29.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic and functional characterisation of platelet microparticle size classes.
Thromb Haemost. 2009 Oct;102(4):711-8. doi: 10.1160/TH09-04-243.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes.
Mol Cell Proteomics. 2010 Jun;9(6):1085-99. doi: 10.1074/mcp.M900381-MCP200. Epub 2010 Feb 1.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomics of microparticles after deep venous thrombosis.
Thromb Res. 2010 Jun;125(6):e269-74. doi: 10.1016/j.thromres.2010.01.019. Epub 2010 Feb 13.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Protein profile of exosomes from trabecular meshwork cells.
J Proteomics. 2011 May 16;74(6):796-804. doi: 10.1016/j.jprot.2011.02.024. Epub 2011 Mar 8.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles derived from human colorectal cancer ascites.
Proteomics. 2011 Jul;11(13):2745-51. doi: 10.1002/pmic.201100022. Epub 2011 Jun 1.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT).
Proteomics. 2012 Jan;12(2):329-38. doi: 10.1002/pmic.201100477. Epub 2011 Dec 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles derived from human mesenchymal stem cells.
J Proteome Res. 2012 Feb 3;11(2):839-49. doi: 10.1021/pr200682z. Epub 2011 Dec 28.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527The protein interaction network of extracellular vesicles derived from human colorectal cancer cells.
J Proteome Res. 2012 Feb 3;11(2):1144-51. doi: 10.1021/pr200842h. Epub 2012 Jan 9.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteome profiling of normal human circulating microparticles.
J Proteome Res. 2012 Apr 6;11(4):2154-63. doi: 10.1021/pr200901p. Epub 2012 Mar 1.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles in human saliva by gel electrophoresis with liquid chromatography-mass spectrometry.
Anal Chim Acta. 2012 Apr 20;723:61-7. doi: 10.1016/j.aca.2012.02.018. Epub 2012 Feb 19.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3.
Mol Cell Proteomics. 2012 Jul;11(7):M111.012914. doi: 10.1074/mcp.M111.012914. Epub 2012 Mar 28.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Biochemical and physical characterisation of urinary nanovesicles following CHAPS treatment.
PLoS One. 2012;7(7):e37279. doi: 10.1371/journal.pone.0037279. Epub 2012 Jul 12.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Biochemical and physical characterisation of urinary nanovesicles following CHAPS treatment.
PLoS One. 2012;7(7):e37279. doi: 10.1371/journal.pone.0037279. Epub 2012 Jul 12.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles.
PLoS One. 2012;7(7):e42064. doi: 10.1371/journal.pone.0042064. Epub 2012 Jul 27.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.
Int J Proteomics. 2012;2012:971907. doi: 10.1155/2012/971907. Epub 2012 Jul 18.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy.
PLoS One. 2012;7(10):e46822. doi: 10.1371/journal.pone.0046822. Epub 2012 Oct 8.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.
Mol Cell Proteomics. 2013 Feb;12(2):343-55. doi: 10.1074/mcp.M112.022806. Epub 2012 Nov 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.
Mol Cell Proteomics. 2013 Feb;12(2):343-55. doi: 10.1074/mcp.M112.022806. Epub 2012 Nov 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.
Mol Cell Proteomics. 2013 Feb;12(2):343-55. doi: 10.1074/mcp.M112.022806. Epub 2012 Nov 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases.
PLoS One. 2012;7(11):e49726. doi: 10.1371/journal.pone.0049726. Epub 2012 Nov 20.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases.
PLoS One. 2012;7(11):e49726. doi: 10.1371/journal.pone.0049726. Epub 2012 Nov 20.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases.
PLoS One. 2012;7(11):e49726. doi: 10.1371/journal.pone.0049726. Epub 2012 Nov 20.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Characterization and proteomic analysis of ovarian cancer-derived exosomes.
J Proteomics. 2013 Jan 16;80C:171-182. doi: 10.1016/j.jprot.2012.12.029.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.
J Proteomics. 2013 Apr 26;82:193-229. doi: 10.1016/j.jprot.2013.01.012. Epub 2013 Jan 30.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells.
Proteomics. 2013 Apr;13(7):1108-20. doi: 10.1002/pmic.201200531.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components.
Proteomics. 2013 May;13(10-11):1672-86. doi: 10.1002/pmic.201200562.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components.
Proteomics. 2013 May;13(10-11):1672-86. doi: 10.1002/pmic.201200562.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions.
Proteomics. 2013 Jul;13(14):2125-34. doi: 10.1002/pmic.201200323.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic characterization of human platelet-derived microparticles.
Anal Chim Acta. 2013 May 7;776:57-63. doi: 10.1016/j.aca.2013.03.023. Epub 2013 Mar 19.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system.
Cell Host Microbe. 2013 May 15;13(5):521-34. doi: 10.1016/j.chom.2013.04.009.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Modulation of B-cell exosome proteins by gamma herpesvirus infection.
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):E2925-33. doi: 10.1073/pnas.1303906110. Epub 2013 Jul 1.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis.
PLoS One. 2013 Jul 8;8(7):e68451. doi: 10.1371/journal.pone.0068451. Print 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells.
J Extracell Vesicles. 2012 Sep 11;1. doi: 10.3402/jev.v1i0.18704. eCollection 2012.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells.
J Extracell Vesicles. 2012 Sep 11;1. doi: 10.3402/jev.v1i0.18704. eCollection 2012.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes.
J Extracell Vesicles. 2012 Apr 16;1. doi: 10.3402/jev.v1i0.18396. eCollection 2012.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression.
PLoS One. 2013 Sep 19;8(9):e75054. doi: 10.1371/journal.pone.0075054. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis.
J Proteomics. 2014 Jan 16;96:92-102. doi: 10.1016/j.jprot.2013.10.037. Epub 2013 Nov 7.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis.
J Proteomics. 2014 Jan 16;96:92-102. doi: 10.1016/j.jprot.2013.10.037. Epub 2013 Nov 7.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients.
J Extracell Vesicles. 2013 Dec 23;2. doi: 10.3402/jev.v2i0.22097. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients.
J Extracell Vesicles. 2013 Dec 23;2. doi: 10.3402/jev.v2i0.22097. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Exosomal proteins in the aqueous humor as novel biomarkers in patients with neovascular age-related macular degeneration.
J Proteome Res. 2014 Feb 7;13(2):581-95. doi: 10.1021/pr400751k. Epub 2014 Jan 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem Biophys Res Commun. 2014 Mar 21;445(4):694-701. doi: 10.1016/j.bbrc.2013.12.070. Epub 2014 Jan 14.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Quantitative proteomics of extracellular vesicles released from human monocyte-derived macrophages upon beta-glucan stimulation.
J Proteome Res. 2014 May 2;13(5):2468-77. doi: 10.1021/pr4012552. Epub 2014 Apr 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Human urinary exosomes as innate immune effectors.
J Am Soc Nephrol. 2014 Sep;25(9):2017-27. doi: 10.1681/ASN.2013101066. Epub 2014 Apr 3.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
J Proteomics. 2014 Jun 25;106:191-204. doi: 10.1016/j.jprot.2014.04.028. Epub 2014 Apr 24.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Exosome-mediated extracellular release of polyadenylate-binding protein 1 in human metastatic duodenal cancer cells.
Proteomics. 2014 Jul 27. doi: 10.1002/pmic.201300477.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Extravillous trophoblast cells-derived exosomes promote vascular smooth muscle cell migration.
Front Pharmacol. 2014 Aug 11;5:175. doi: 10.3389/fphar.2014.00175. eCollection 2014.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes.
Sci Rep. 2014 Aug 29;4:6232. doi: 10.1038/srep06232.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication.
Mol Cell Proteomics. 2014 Sep 30. pii: mcp.M114.041194.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Intraluminal proteome and peptidome of human urinary extracellular vesicles.
Proteomics Clin Appl. 2014 Dec 4. doi: 10.1002/prca.201400085.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Perturbations in the urinary exosome in transplant rejection.
Front Med (Lausanne). 2015 Jan 5;1:57. doi: 10.3389/fmed.2014.00057. eCollection 2014.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Human thymic epithelial primary cells produce exosomes carrying tissue-restricted antigens.
Immunol Cell Biol. 2015 Mar 17. doi: 10.1038/icb.2015.33.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Exosomes released from breast cancer carcinomas stimulate cell movement.
PLoS One. 2015 Mar 23;10(3):e0117495. doi: 10.1371/journal.pone.0117495. eCollection 2015.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Oncotarget. 2015 Mar 12.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Identification of distinct circulating exosomes in Parkinson's disease.
Ann Clin Transl Neurol. 2015 Apr;2(4):353-61. doi: 10.1002/acn3.175. Epub 2015 Feb 6.		ENOG4111C5Z318 / 0 / 318
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9)P35527Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes.
Oncotarget. 2015 Apr 12.		ENOG4111C5Z318 / 0 / 318
[1] [2] [3] [4]